TASLY(SH:600535) Huan Qiu Lao Hu Cai Jing·2025-09-23 02:03Group 1: Product and Market Potential - Puyouke is a first-class biological innovative drug approved under the "Major New Drug Creation" project, now gaining approval for acute ischemic stroke indication, marking its second indication in China [1] - Compared to other thrombolytic drugs, Puyouke has a unique thrombolytic mechanism with lower systemic bleeding risk and high safety, showing a significantly lower rate of symptomatic intracranial hemorrhage in clinical trials [1] - In 2019, there were 3.94 million new stroke cases in China, with ischemic strokes accounting for 2.87 million (72.8%), indicating a growing market for stroke treatment [2] Group 2: Industry Trends and Treatment Rates - The incidence of ischemic stroke in China increased from 117 per 100,000 in 2005 to 145 per 100,000 in 2019, with an annual growth rate of 4-6% [2] - The treatment rates for acute ischemic stroke in China are still low, with intravenous thrombolysis at 5.64% and endovascular treatment at only 1.45% in 2019-2020, suggesting significant room for improvement [2] Group 3: Company Innovation and Pipeline - Tianshili is focused on dual-engine innovation in traditional Chinese medicine and biological drugs, with 31 innovative drugs in its pipeline [3] - The company has made significant progress in both traditional and biological drug sectors, with multiple products in late-stage clinical trials [3] - Following its integration with China Resources Sanjiu, Tianshili aims to become a leading innovative pharmaceutical company in China, with a clear strategy for its research pipeline that has yet to be fully valued by the market [3]